تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
DuPont de Nemours, Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $17.6B | |
|---|---|---|
| Revenue (ttm) | 7B | |
| Net income (ttm) | 55M | |
| EPS (ttm) | $0.39 | |
| Shares out | 135M | |
| P/E (trailing) | 356.0x | |
| P/E (forward) | 16.5x | |
| Dividend | $2.40 (1.74%) | |
| Volume | 369,186 | |
| Beta | 1.08 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $12.57B | $13.02B | $6.61B | $6.72B | $6.85B | -14.1% |
| Gross profit | $4.03B | $4.03B | $3.63B | $3.91B | $2.07B | -15.3% |
| Operating income | $1.97B | $1.94B | $900.0M | $1.56B | $513.0M | -28.6% |
| Net income | $6.47B | $5.87B | $423.0M | $703.0M | $-779.0M | — |
| EPS (diluted) | $14.92 | $14.75 | $2.82 | $5.04 | $-5.58 | — |
| EBITDA | $3.08B | $3.08B | $2.05B | $2.75B | $1.16B | -21.7% |
| R&D | $557.0M | $536.0M | $192.0M | $203.0M | $193.0M | -23.3% |
| SG&A | $1.60B | $1.47B | $891.0M | $976.0M | $1.02B | -10.7% |
Recent company headlines from major financial publishers.
In the modal base case, DuPont delivers on guided 2H operational acceleration, achieving $7,166M in FY2026 revenue and adjusted EPS of $7.26, followed by FY2027 revenue of $7,451M and EPS of $7.97. Operating EBIT margins expand steadily from 13.5% in 2026 to 15.0% by 2030 through 80/20 productivity gains. Free cash flow conversion remains near 100%, supporting $250M quarterly share repurchases. Intrinsic fair value converges to $100.11, indicating that trading at $130.00 is significantly stretched.
In the upside scenario, rapid realization of 80/20 restructuring efficiencies and sustained mid-single-digit organic growth in Healthcare & Water Technologies expand operating EBIT margins toward 17.0%, while sequential volume exit acceleration (6% in 2H 2026, 7% in Q4) and disciplined buybacks drive FY2027 EPS growth to 12.0%, supporting intrinsic fair value of 128.56.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 8.5% | $108 | $110 | $113 | $115 | $118 |
| 9.0% | $102 | $104 | $106 | $108 | $111 |
| 9.5% | $96.9 | $98.4 | $100 | $102 | $104 |
| 10.0% | $92.1 | $93.5 | $94.9 | $96.4 | $98.1 |
| 10.5% | $87.9 | $89.1 | $90.3 | $91.6 | $93.0 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
